Roberto Urquiza, MD
Internal Medicine · Miami Lakes, FLNPI 1225038151
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,600 of the $5,849 with a category attached, or 61.5%. Amgen accounts for 68.3% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2019 at $4,144 and has fallen 94.2% since, to $241 in 2025. Among internal medicine clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 91 payments — averaging $64.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$4K
- Bayer$335
- Radius Health, Inc.$308
- Johnson & Johnson$204
- Esperion Therapeutics, Inc.$153
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$139
- plus $718 from 18 others
What the payments were for
- Consulting fees$3,60062%
- Travel & lodging$1863%
- Food & beverage$2,04235%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 8 | $3,992 |
| Bayer | 15 | $335 |
| Radius Health, Inc. | 15 | $308 |
| Johnson & Johnson | 11 | $204 |
| Esperion Therapeutics, Inc. | 2 | $153 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $139 |
| Pfizer | 4 | $91 |
| Novo Nordisk | 4 | $80 |
| Sumitomo Pharma America, Inc. | 3 | $71 |
| Lundbeck LLC | 2 | $64 |
| Otsuka America Pharmaceutical, Inc. | 3 | $61 |
| AbbVie(2 entities) | 3 | $46 |
| Exact Sciences | 2 | $43 |
| Gilead | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $35 |
| GSK | 1 | $26 |
| Abbott | 1 | $26 |
| Lilly USA, LLC | 1 | $25 |
| Alvogen Inc | 1 | $23 |
| Arbor Pharmaceuticals, Inc. | 1 | $21 |
| Haemonetics Corporation | 1 | $20 |
| Novartis | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,849 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 51 | $56,970 |
| LinzessLinaclotide | 88 | $56,333 |
| EliquisApixaban | 40 | $46,913 |
| EntrestoSacubitril/Valsartan | 28 | $35,761 |
| MyrbetriqMirabegron | 39 | $29,297 |
| XareltoRivaroxaban | 22 | $25,353 |
| ProliaDenosumab | 11 | $19,284 |
| TradjentaLinagliptin | 14 | $18,033 |
| MounjaroTirzepatide | 15 | $16,467 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $8,810 |
| SynthroidLevothyroxine Sodium | 60 | $8,348 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $6,328 |
| PremarinEstrogens, Conjugated | 12 | $5,839 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 50 | $4,630 |
| Memantine Hcl ErMemantine Hcl | 30 | $4,180 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Synthroid | $46 | $64,681148 claims |
| MerckJanuvia | $13 | $56,97051 claims |
| PfizerEliquis, Premarin, Paxlovid | $91 | $54,18163 claims |
| NovartisEntresto | $18 | $35,76128 claims |
| Johnson & JohnsonXarelto | $204 | $25,35322 claims |
| Lilly USA, LLCMounjaro, Humalog | $25 | $19,41226 claims |
| AmgenProlia | $3,992 | $19,28411 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $26 | $15,13825 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Miami Lakes
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
- Julio ConradoFort Myers$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.